BID | 150.00 | ASK | 161.00 | ||
Open | 159.27 | Previous Close | 159.20 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 181.71 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 14.64 | Finscreener Ranking | ★★★ 50.66 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 50.28 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 48.14 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Market Cap | 15.92B | Earnings Rating | Strong Sell | |
Price Range Ratio 52W % | 79.79 | Earnings Date | 6th May 2021 |
Today's Price Range 156.35159.66 | 52W Range 69.37181.07 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 0.85% | ||
1 Month | 8.67% | ||
3 Months | -0.50% | ||
6 Months | 56.93% | ||
1 Year | 129.37% | ||
3 Years | - | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -24.08 | |||
ROE last 12 Months | -23.41 | |||
ROA (5Y Avg) | -6.88 | |||
ROA last 12 Months | -15.29 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -20.16 | |||
Return on invested Capital Q | -5.57 | |||
Return on invested Capital Y | -17.23 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 4.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-61.80 | ||||
12.34 | ||||
71.01 | ||||
- | ||||
-136.70 | ||||
-1.07 | ||||
12.53 | ||||
12.93 | ||||
15.08B | ||||
Forward PE | -61.87 | |||
PEG | -6.79 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
27.70 | ||||
28.30 | ||||
0.40 | ||||
0.66 | ||||
-50.60 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
67.70 | ||||
-64.60 | ||||
-58.30 | ||||
-112.20 | ||||
-99.57 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
219.22M | ||||
2.18 | ||||
68.93 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | -0.44 | -0.94 | -113.64 |
Q03 2020 | -0.34 | -0.78 | -129.41 |
Q02 2020 | -0.40 | -0.57 | -42.50 |
Q01 2020 | -0.38 | -0.29 | 23.68 |
Q04 2019 | -0.30 | -0.27 | 10.00 |
Q03 2019 | -0.39 | -0.14 | 64.10 |
Q02 2019 | -0.34 | -0.13 | 61.76 |
Q01 2019 | -0.35 | -0.30 | 14.29 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | -0.82 | -78.26 | Negative |
6/2021 QR | -0.78 | -105.26 | Negative |
12/2021 FY | -3.38 | -154.14 | Negative |
12/2022 FY | -2.54 | -568.42 | Negative |
Next Report Date | 6th May 2021 |
Estimated EPS Next Report | -0.82 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | 9.10 |
Volume Overview | |
---|---|
Volume | 468.45K |
Shares Outstanding | 100.43M |
Trades Count | 9.51K |
Dollar Volume | 451.78M |
Avg. Volume | 1.02M |
Avg. Weekly Volume | 615.49K |
Avg. Monthly Volume | 799.98K |
Avg. Quarterly Volume | 972.52K |
Guardant Health Inc. (NASDAQ: GH) stock closed at 158.5 per share at the end of the most recent trading day (a -0.44% change compared to the prior day closing price) with a volume of 468.72K shares and market capitalization of 15.92B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 864 people. Guardant Health Inc. CEO is Helmy Eltoukhy.
The one-year performance of Guardant Health Inc. stock is 129.37%, while year-to-date (YTD) performance is 22.98%. GH stock has a five-year performance of %. Its 52-week range is between 69.37 and 181.07, which gives GH stock a 52-week price range ratio of 79.79%
Guardant Health Inc. currently has a PE ratio of -61.80, a price-to-book (PB) ratio of 12.34, a price-to-sale (PS) ratio of 71.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -15.29%, a ROC of -20.16% and a ROE of -23.41%. The company’s profit margin is -99.57%, its EBITDA margin is -58.30%, and its revenue ttm is $219.22 Million , which makes it $2.18 revenue per share.
Of the last four earnings reports from Guardant Health Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Guardant Health Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Guardant Health Inc. is Strong Buy (1), with a target price of $181.71, which is +14.64% compared to the current price. The earnings rating for Guardant Health Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Guardant Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Guardant Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.08, ATR14 : 8.68, CCI20 : 61.98, Chaikin Money Flow : 0.11, MACD : -0.66, Money Flow Index : 70.35, ROC : 7.98, RSI : 42.17, STOCH (14,3) : 80.33, STOCH RSI : 0.96, UO : 55.60, Williams %R : -19.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Guardant Health Inc. in the last 12-months were: AmirAli Talasaz (Option Excercise at a value of $1 171 040), AmirAli Talasaz (Sold 2 151 656 shares of value $272 299 241 ), Derek A. Bertocci (Option Excercise at a value of $89 615), Derek A. Bertocci (Sold 97 089 shares of value $8 961 132 ), Dipchand Nishar (Sold 2 shares of value $200 ), Helmy Eltoukhy (Option Excercise at a value of $622 498), Helmy Eltoukhy (Sold 1 860 334 shares of value $262 721 024 ), Ian T. Clark (Option Excercise at a value of $155 170), Ian T. Clark (Sold 37 122 shares of value $3 612 841 ), Michael Wiley (Option Excercise at a value of $41 800), Michael Wiley (Sold 10 000 shares of value $787 042 ), Samir Kaul (Sold 45 000 shares of value $4 571 543 ), Stanley J. Meresman (Option Excercise at a value of $514 939), Stanley J. Meresman (Sold 86 690 shares of value $9 134 504 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
CEO: Helmy Eltoukhy
Telephone: +1 855 698-8887
Address: 505 Penobscot Drive, Redwood City 94063, CA, US
Number of employees: 864
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.